FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912148172> ?p ?o ?g. }

• W2912148172 endingPage "1170" @default.
• W2912148172 startingPage "1160" @default.
• W2912148172 abstract "// Yoshiaki Abe 1, * , Tetsuya Kobayashi 2, * , Yoshiaki Usui 3 , Kentaro Narita 1 , Hiroki Kobayashi 1 , Akihiro Kitadate 1 , Daisuke Miura 1 , Masami Takeuchi 1 and Kosei Matsue 1 1 Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Chiba, Japan 2 Division of Cardiology, Kameda Medical Center, Chiba, Japan 3 Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Centre Research Institute, Aichi, Japan * These authors contributed equally to this work Correspondence to: Yoshiaki Abe, email: yoshiakiabe1018@gmail.com Keywords: diastolic dysfunction; frailty; multiple myeloma; N-terminal pro-brain natriuretic peptide; prognosis Received: October 30, 2018      Accepted: January 21, 2019      Published: February 01, 2019 ABSTRACT We retrospectively explored the prognostic relevance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and the association of NT-proBNP with cardiac and renal functions in 153 patients with newly diagnosed symptomatic multiple myeloma and no concomitant light chain amyloidosis who received novel agents. We also examined the usefulness of the new frailty system recently introduced by Mayo Clinic (combining age, performance status, and NT-proBNP). Patients with higher NT-proBNP levels (≥300 ng/L) had a significantly higher incidence of left ventricular diastolic dysfunction (LVDD) and myeloma-related renal insufficiency and significantly shorter overall survival (OS) than did those with lower NT-proBNP levels (<300 ng/L). NT-proBNP remained predictive of OS on multivariate analysis. Mayo Clinic’s new frailty system showed excellent discrimination of OS. Furthermore, the Instrumental Activity of Daily Living (IADL) score (not evaluated in Mayo Clinic’s study) predicted OS independently of this system, and a sharper discrimination of OS curves was obtained by the incorporation of IADL into this system. Our findings demonstrated that NT-proBNP levels were associated with both LVDD (as a host risk factor) and myeloma-related renal insufficiency (resulting from the disease aggressiveness) and provided predictive information regarding OS in patients with symptomatic myeloma. Furthermore, we, for the first time, validated Mayo Clinic’s new frailty system. Our modification further improved Mayo Clinic’s system by newly incorporating the IADL score." @default.
• W2912148172 created "2019-02-21" @default.
• W2912148172 creator A5010746455 @default.
• W2912148172 creator A5013888998 @default.
• W2912148172 creator A5018994607 @default.
• W2912148172 creator A5020298977 @default.
• W2912148172 creator A5025340212 @default.
• W2912148172 creator A5042882487 @default.
• W2912148172 creator A5068665957 @default.
• W2912148172 creator A5072832689 @default.
• W2912148172 creator A5087813809 @default.
• W2912148172 date "2019-02-01" @default.
• W2912148172 modified "2023-09-25" @default.
• W2912148172 title "N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma" @default.
• W2912148172 cites W1970296650 @default.
• W2912148172 cites W1992144322 @default.
• W2912148172 cites W2002773837 @default.
• W2912148172 cites W2006382315 @default.
• W2912148172 cites W2046578145 @default.
• W2912148172 cites W2048483323 @default.
• W2912148172 cites W2053219593 @default.
• W2912148172 cites W2056955741 @default.
• W2912148172 cites W2066800926 @default.
• W2912148172 cites W2067450773 @default.
• W2912148172 cites W2075117520 @default.
• W2912148172 cites W2085449719 @default.
• W2912148172 cites W2099510363 @default.
• W2912148172 cites W2106421416 @default.
• W2912148172 cites W2118848299 @default.
• W2912148172 cites W2120474651 @default.
• W2912148172 cites W2128192762 @default.
• W2912148172 cites W2137040543 @default.
• W2912148172 cites W2140468511 @default.
• W2912148172 cites W2144728882 @default.
• W2912148172 cites W2149918298 @default.
• W2912148172 cites W2153845023 @default.
• W2912148172 cites W2171033052 @default.
• W2912148172 cites W2256869561 @default.
• W2912148172 cites W2313186535 @default.
• W2912148172 cites W2328176404 @default.
• W2912148172 cites W2469889813 @default.
• W2912148172 cites W2486629951 @default.
• W2912148172 cites W2516556835 @default.
• W2912148172 cites W2545893020 @default.
• W2912148172 cites W2728236509 @default.
• W2912148172 cites W2771890341 @default.
• W2912148172 cites W2871372177 @default.
• W2912148172 cites W2905042952 @default.
• W2912148172 cites W4211058750 @default.
• W2912148172 doi "https://doi.org/10.18632/oncotarget.26647" @default.
• W2912148172 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6383683" @default.
• W2912148172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30800225" @default.
• W2912148172 hasPublicationYear "2019" @default.
• W2912148172 type Work @default.
• W2912148172 sameAs 2912148172 @default.
• W2912148172 citedByCount "2" @default.
• W2912148172 countsByYear W29121481722021 @default.
• W2912148172 countsByYear W29121481722022 @default.
• W2912148172 crossrefType "journal-article" @default.
• W2912148172 hasAuthorship W2912148172A5010746455 @default.
• W2912148172 hasAuthorship W2912148172A5013888998 @default.
• W2912148172 hasAuthorship W2912148172A5018994607 @default.
• W2912148172 hasAuthorship W2912148172A5020298977 @default.
• W2912148172 hasAuthorship W2912148172A5025340212 @default.
• W2912148172 hasAuthorship W2912148172A5042882487 @default.
• W2912148172 hasAuthorship W2912148172A5068665957 @default.
• W2912148172 hasAuthorship W2912148172A5072832689 @default.
• W2912148172 hasAuthorship W2912148172A5087813809 @default.
• W2912148172 hasBestOaLocation W29121481721 @default.
• W2912148172 hasConcept C120665830 @default.
• W2912148172 hasConcept C121332964 @default.
• W2912148172 hasConcept C126322002 @default.
• W2912148172 hasConcept C143998085 @default.
• W2912148172 hasConcept C164705383 @default.
• W2912148172 hasConcept C194409129 @default.
• W2912148172 hasConcept C2775915353 @default.
• W2912148172 hasConcept C2776364478 @default.
• W2912148172 hasConcept C2778198053 @default.
• W2912148172 hasConcept C2779384505 @default.
• W2912148172 hasConcept C57900726 @default.
• W2912148172 hasConcept C61511704 @default.
• W2912148172 hasConcept C71924100 @default.
• W2912148172 hasConcept C84393581 @default.
• W2912148172 hasConceptScore W2912148172C120665830 @default.
• W2912148172 hasConceptScore W2912148172C121332964 @default.
• W2912148172 hasConceptScore W2912148172C126322002 @default.
• W2912148172 hasConceptScore W2912148172C143998085 @default.
• W2912148172 hasConceptScore W2912148172C164705383 @default.
• W2912148172 hasConceptScore W2912148172C194409129 @default.
• W2912148172 hasConceptScore W2912148172C2775915353 @default.
• W2912148172 hasConceptScore W2912148172C2776364478 @default.
• W2912148172 hasConceptScore W2912148172C2778198053 @default.
• W2912148172 hasConceptScore W2912148172C2779384505 @default.
• W2912148172 hasConceptScore W2912148172C57900726 @default.
• W2912148172 hasConceptScore W2912148172C61511704 @default.
• W2912148172 hasConceptScore W2912148172C71924100 @default.
• W2912148172 hasConceptScore W2912148172C84393581 @default.
• W2912148172 hasIssue "10" @default.

• next